Copyright
©The Author(s) 2021.
World J Clin Oncol. Aug 24, 2021; 12(8): 656-663
Published online Aug 24, 2021. doi: 10.5306/wjco.v12.i8.656
Published online Aug 24, 2021. doi: 10.5306/wjco.v12.i8.656
Table 2 Number of mutations found in genetic testing of lung cancer patients
| EGFR-pos | BRAF pos | KRAS pos | cfDNA EGFR-pos | ALK-pos | ROS-1-pos | |
| 2016 | 2 (5%) | NR | NR | 1 (20%) | 0 | 0 |
| 2017 | 2 (5%) | NR | NR | 2 (20%) | 0 | 0 |
| 2018 | 6 (12%) | 1 (2%) | 9 (18%) | 6 (21%) | 2 (4%) | 0 |
| 2019 | 6 (18%) | 2 (6%) | 10 (30%) | 3 (25%) | 0 | 0 |
- Citation: Saarenheimo J, Andersen H, Eigeliene N, Jekunen AP. Current challenges in applying gene-driven therapies in clinical lung cancer practice. World J Clin Oncol 2021; 12(8): 656-663
- URL: https://www.wjgnet.com/2218-4333/full/v12/i8/656.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i8.656